Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States

Robert Ohsfeldt, PhD1,2; Kari Kelton, PhD2; Tim Klein2; Mark Belge3; Patrick L. Collam, PharmD3; Theodore Spiro, MD3; Russel Burge, PhD3,4; and Neera Ahuja, MD5

1Texas A&M University, College Station, Texas; 2Medical Decision Modeling Inc, Indianapolis, Indiana; 3Eli Lilly and Company, Indianapolis, Indiana; 4University of Cincinnati, Cincinnati, Ohio; and 5Stanford University, Palo Alto, California

ABSTRACT

Purpose: In the Phase III COV-BARRIER (Efficacy and Safety of Baricitinib for the Treatment of Hospitalised Adults With COVID-19) trial, treatment with baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC), was associated with significantly reduced mortality over 28 days in hospitalized patients with coronavirus disease–2019 (COVID-19), with a safety profile similar to that of SOC alone. This study assessed the cost-effectiveness of baricitinib + SOC versus SOC alone (which included systemic corticosteroids and remdesivir) in hospitalized patients with COVID-19 in the United States.

Methods: An economic model was developed to simulate inpatients’ stay, discharge to postacute care, and recovery. Costs modeled included payor costs, hospital costs, and indirect costs. Benefits modeled included life-years (LYs) gained, quality-adjusted life-years (QALYs) gained, deaths avoided, and use of mechanical ventilation avoided. The primary analysis was performed from a payor perspective over a lifetime horizon; a secondary analysis was performed from a hospital perspective. The base-case analysis modeled the numeric differences in treatment effectiveness observed in the COV-BARRIER trial. Scenario analyses were also performed in which the clinical benefit of baricitinib was limited to the statistically significant reduction in mortality demonstrated in the trial.

Findings: In the base-case payor perspective model, an incremental total cost of 17,276 US dollars (USD), total QALYs gained of 0.6703, and total LYs gained of 0.837 were found with baricitinib + SOC compared with SOC alone. With the addition of baricitinib, survival was increased by 5.1% and the use of mechanical ventilation was reduced by 1.6%. The base-case incremental cost-effectiveness ratios were 25,774 USD/QALY gained and 20,638 USD/LY gained; a “mortality-only” scenario analysis yielded similar results of 26,862 USD/QALY gained and 21,433 USD/LY gained. From the hospital perspective, combination treatment with baricitinib + SOC was more effective and less costly than was SOC alone in the base case, with an incremental cost of 38,964 USD per death avoided in the mortality-only scenario.

Implications: In hospitalized patients with COVID-19 in the United States, the addition of baricitinib to SOC was cost-effective. Cost-effectiveness was demonstrated from both the payor and the hospital perspectives. These findings were robust to sensitivity analysis and to conservative assumptions limiting the clinical benefits of baricitinib to the statistically significant reduction in mortality demonstrated in the COV-BARRIER trial. (Clin Ther. 2021;43:1877–1893.) © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords: baricitinib, cost-effectiveness, COVID-19, hospital, mechanical ventilation, mortality.
INTRODUCTION
Coronavirus disease–2019 (COVID-19), caused by the novel severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China, and reported to the World Health Organization at the end of 2019. By March 2020, a global pandemic was declared by the World Health Organization. The cumulative number of confirmed global cases of COVID-19 by June 2021 was 178.8 million, with 3.9 million deaths. Also as of June 2021, the United States reported 33.2 million confirmed cases of COVID-19, with 597,037 deaths.

Cost impacts and capacity-related constraints have proved to be large burdens to hospitals and health care systems during the global pandemic. As of June 2021 in the United States, 65% of the population aged 18+ years had received at least one dose of a COVID-19 vaccine, 150.8 million were fully vaccinated, and hospitalizations had decreased from a peak 7-day mean of 16,492 in January to just 1824 in June. However, vaccine availability and current vaccination levels do not diminish the need for effective and cost-effective treatments for hospitalized patients with COVID-19, which can reduce the severity of the disease and the resultant resource and cost burdens on hospitals. Although vaccines have been demonstrated to be clinically effective, they are not 100% effective, and not everyone can receive them (eg, those taking immunosuppressant drugs). Also, considering the time it takes to vaccinate the population and the uncertainty with the emergence of multiple variants, even with increased vaccination rates, COVID-19 will continue to consume important in-hospital health care resources.

Combination treatment with the immunomodulator baricitinib and the antiviral remdesivir was approved by the US Food and Drug Administration under emergency use authorization for the treatment of hospitalized patients with COVID-19 requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. The second stage of the Phase III Adaptive COVID-19 Treatment Trial (ACTT-2) demonstrated the effectiveness of baricitinib + remdesivir over remdesivir alone in reducing recovery time and accelerating improvement in clinical status in hospitalized patients with COVID-19, specifically among those receiving high-flow oxygen or noninvasive ventilation. The subsequent Phase III COV-BARRIER (Efficacy and Safety of Baricitinib for the Treatment of Hospitalised Adults With COVID-19) trial, which evaluated combination treatment with baricitinib + standard of care (SOC), demonstrated statistically significant reductions in 28- and 60-day all-cause mortality compared with SOC alone (including large percentages of patients receiving dexamethasone and remdesivir). The study demonstrated numerically but statistically nonsignificantly lesser rates of progression to noninvasive ventilation and to mechanical ventilation.

Clinical and economic outcomes with the use of remdesivir in hospitalized patients with COVID-19 were assessed by the Institute for Clinical and Economic Review. That assessment was based on clinical data on the efficacy of remdesivir versus SOC from ACTT-1. The Institute for Clinical and Economic Review later published an updated evaluation of remdesivir + SOC in the populations with mild disease and moderate to severe disease, separately, based on clinical evidence from several trials. The model by the Institute for Clinical and Economic Review did not account for the discharge status of patients requiring postacute care, or the prevalence of comorbidities among hospitalized patients with COVID-19, nor did it consider the hospital perspective.

To address these limitations, the present cost-effectiveness analysis (CEA) used a model that reflected the patient’s in-hospital experience and postacute hospital consequences. The overall cost burden on payors and the impact of resource utilization on hospitals are large; therefore, more evidence is needed to guide the efficient utilization of resources. This CEA of baricitinib + SOC versus placebo + SOC used data from the COV-BARRIER trial by replicating and extending the cost-effectiveness model (CEM) developed by the Institute for Clinical and Economic Review.

PARTICIPANTS AND METHODS
Population and Perspective
A pharmacoeconomic model was developed to estimate the cost-effectiveness of baricitinib + SOC treatment in hospitalized patients aged ≥18 years with COVID-19 in the United States. Although eligible patients did not require invasive mechanical ventilation at admission, a percentage had various other severe comorbidities. The model was constructed to analyze cost-effectiveness from the perspective of a third-party payor or from the narrow perspective of a hospital. The primary analysis was performed from the payor
Modeling the new mortality, ventilation, without related in duration discharge cal gained, adjusted Modeled with Related as (PSAs), using The long-term hospital indirect as perspective, Inpatient hospital payments the model COV-BARRIER ventilation/noninvasive the overall mechanical oxygen, of mechanical ventilation, and COVID-19–related mortality, due to therapy intervention. Health outcomes represented in the model were based on the National Institute of Allergy and Infectious Disease–Ordinal Scale (OS) score, used to measure efficacy in the COV-BARRIER trial; inpatients’ hospital-related outcomes in the CEM included medical care without oxygen, supplemental oxygen, noninvasive ventilation, mechanical ventilation, and death. Mortality, overall time to recovery, duration of mechanical ventilation/noninvasive ventilation/supplemental oxygen, percentage of patients who progressed to new use of mechanical ventilation/noninvasive ventilation/supplemental oxygen, and the effects of treatment on the discharge status of patients were simulated in the model as treatment effects and were derived from the COV-BARRIER results (data on file, Eli Lilly and Company, 2021).

Modeled Economic and Health Outcomes

The measures of benefit in the model were quality-adjusted life-years (QALYs) gained, life-years (LYs) gained, number of deaths avoided, and use of mechanical ventilation, accrued during hospitalization and after discharge of patients to quantify the impact of reducing progression to greater oxygen support level of care, duration of mechanical ventilation, and COVID-19–related mortality, due to therapy intervention. Health outcomes represented in the model were based on the National Institute of Allergy and Infectious Disease–Ordinal Scale (OS) score, used to measure efficacy in the COV-BARRIER trial; inpatients’ hospital-related outcomes in the CEM included medical care without oxygen, supplemental oxygen, noninvasive ventilation, mechanical ventilation, and death. Mortality, overall time to recovery, duration of mechanical ventilation/noninvasive ventilation/supplemental oxygen, percentage of patients who progressed to new use of mechanical ventilation/noninvasive ventilation/supplemental oxygen, and the effects of treatment on the discharge status of patients were simulated in the model as treatment effects and were derived from the COV-BARRIER results (data on file, Eli Lilly and Company, 2021).

Model Framework

The CEM was structured as a sequence of three submodels: inpatient, discharged, and recovered (Figure 1). Descriptions of the three submodels are presented here; additional details of the model structure are provided in the Appendix. The inpatient submodel simulates treatment effects on new use of oxygen support, the total LOS, the number of days (duration of care) at each level of oxygen support, and the probabilities of survival and recovery. Inpatient hospital expenditures were based on MS-DRGs for COVID-19 admissions. It was assumed that the highest level of oxygen support received determined the DRG for the purposes of estimating payments to hospitals. For analysis from the hospital perspective, hospital expenditures were calculated as the number of days at each level of oxygen support multiplied by the unit-cost per day, based on estimates from a large, all-payer US hospital database with detailed cost information on inpatient discharges. QALYs were calculated as disutilities for COVID-19 symptoms and for each level of oxygen support subtracted from the patients’ age-based utilities. It was assumed that treatment effects on mortality had no impact on inpatient costs or health utilities directly but had downstream effects on the costs, QALYs, and LYs gained accrued in the discharged and recovered submodels.

The discharged submodel simulated postacute care related to COVID-19. Patients could be discharged to one of the following types of discharge care: self-care or custodial care, home health care, inpatient rehabilitation, skilled nursing facility, short-term hospital, long-term acute care hospital, or hospice. In the Premier Healthcare Database (PHD)-based cost analysis, the percentage of patients with each type of discharge care was calculated in patients grouped by the highest level of oxygen support received during the inpatient stay (see Supplemental Table S1). Payor costs of postacute care were calculated as the duration of care multiplied by the unit-cost per day of each type of care. QALYs were calculated as the relative utility of each type of care multiplied by the age-based utilities for the duration of postacute care. The base-case analysis assumed that all patients discharged to hospice died at the end of their stays, and that patients discharged to any status other than self-care or custodial care were unable to work while receiving postacute care.

The recovered submodel simulated all-cause health care costs and all-cause mortality for a lifetime horizon. This submodel assumed that patients recovered from COVID-19 incurred all-cause health care costs, health utilities, and all-cause mortality based on the general non–COVID-19 infected population, adjusted to reflect greater rates of comorbidities in the modeled COVID population.
In the secondary analysis (hospital perspective), only costs and benefits incurred during the inpatient submodel were included, given that the costs after discharge were not covered by the hospital.

**Model Inputs**

**Population**

The key population variables were demographic characteristics, level of care at baseline, and severe comorbidities (Table I). Demographic inputs were based on the intent-to-treat population in COV-BARRIER. The mean age of the recovered subgroup in the model was imputed by the assumption that the relative age of survivors compared with the age of all patients in COV-BARRIER was identical to the relative age of survivors compared with all modeled patients in the Institute for Clinical and Economic Review’s CEA of remdesivir. The percentage of patients with severe comorbidities was used only in the calculation of posthospitalization costs, utilities, and posthospitalization mortality to reflect the greater prevalence of comorbidities among hospitalized patients with COVID-19 compared with the general US population.

The distribution of patients by level of care at baseline (medical care without oxygen, supplemental oxygen, and noninvasive ventilation) was derived from the ordinal scores at baseline in the trial. Patients on mechanical ventilation at study entry were excluded from the trial and from the modeled population.

In the analysis, adjustments were applied to the all-cause health care costs, health utilities, and all-cause mortality in the general population for more representative modeling of the greater prevalence of comorbidities among hospitalized patients with COVID-19. The estimated percentage of patients with severe comorbidities (32.1%) was derived from the prevalence of comorbidities (obesity, diabetes, chronic respiratory disease, and hypertension) in the COV-BARRIER trial population relative to the prevalence of comorbidities in the general population. Multipliers were derived from the research literature to estimate greater all-cause health care costs, reduced quality of life, and greater all-cause mortality associated with metabolic syndrome, which has comorbidity risk factors similar to those of COVID-19 infection and severity (Table I). The postdischarge cost and utility multipliers for severe comorbidities were based on the ratios of per-annum health care costs and EuroQual–Five Dimension utility scores, respectively, in patients with and without metabolic syndrome. The comorbid mortality multiplier was assumed to be the same as the fixed-effects estimate of the relative risk for all-cause mortality (1.37; 95% CI, 1.09–1.74) in a meta-analysis of data from studies that used the most exact definition of metabolic syndrome derived from the World Health Organization.
Table I. Population inputs.

| Parameter | Parameters for Sensitivity Analysis | Study |
|-----------|-------------------------------------|-------|
|           | Value (SE)             | Distribution | Range |       |
| Demographic characteristics |  |  |       |
| Female, % | 36.9 (1.2)          | β            | 34.4–39.3 | Marconi et al\textsuperscript{8} |
| Age at hospital admission, mean, y | 57.6 (0.36)       | Normal       | 56.9–58.3 | Marconi et al\textsuperscript{3} and ACTT-2\textsuperscript{15} |
| Age of patients who recovered, mean, y | 56.2 (0.36)       | Normal       | 55.5–56.9 | Di Fusco et al\textsuperscript{2}, US Bureau of Labor Statistics\textsuperscript{17} |
| Level of care at baseline, % |  | Dirichlet (N = 1525) | Not varied in OWSA | Marconi et al\textsuperscript{8} |
| Mechanical ventilation (OS 7) | 0 | – | – | Data on file, Eli Lilly and Company, 2021 |
| Noninvasive ventilation (OS 6) | 24.4 | – | – | Boudreau et al\textsuperscript{16} |
| Supplemental oxygen (OS 5) | 63.4 | – | – | Vetter et al\textsuperscript{19} |
| Medical care w/o oxygen (OS 4) | 12.3 | – | – | Ford\textsuperscript{20} |
| Severe comorbidities, % | 32.1 (1.2) | β | 29.7–34.4 | Data on file, Eli Lilly and Company, 2021 |
| Postdischarge cost multiplier | 1.601 (0.160) | Normal | 1.287–1.914 | Boudreau et al\textsuperscript{16} |
| Utility multiplier | 0.962 (0.026) | Normal | 0.911–1.014 | Vetter et al\textsuperscript{19} |
| Postdischarge mortality multiplier | 1.37 (0.17) | Normal | 1.09–1.74 | Ford\textsuperscript{20} |

OS = ordinal scale; OWSA = one-way sensitivity analysis.

\*The mean age of patients who recovered in the model was imputed with the assumption that the relative age of survivors compared with the age of all patients in COV-BARRIER was identical to the relative age of survivors compared with all modeled patients in the cost-effectiveness analysis of the remdesivir Institute for clinical and economic review. The SE was assumed to be the same as the SE of the mean age at baseline in all patients in the trial.

**Treatment Effectiveness**

Estimates of treatment effectiveness with baricitinib + SOC and placebo + SOC (Table II) were derived from the intent-to-treat population in COV-BARRIER.\textsuperscript{8} SOC was similar in both study arms and included systemic corticosteroids (79.3\%) and/or remdesivir (18.9\%); 91.6\% of patients who received remdesivir also received a corticosteroid.\textsuperscript{8}

The prevalences of new use of mechanical ventilation and of noninvasive ventilation within each treatment arm were sourced from the corresponding end points in COV-BARRIER (data on file, Eli Lilly and Company, 2021). New use of supplemental oxygen was not reported as an end point and thus was not modeled in the analysis (ie, it was specified as 0\% in both comparator arms). The overall time to recovery within each treatment arm was also sourced from the corresponding end point in COV-BARRIER (data on file, Eli Lilly and Company, 2021). The duration of care at each level of oxygen support was imputed by rescaling of the number of days at each level of oxygen support in ACTT-2\textsuperscript{15} to match the total time to recovery within each treatment arm in COV-BARRIER (data on file, Eli Lilly and Company, 2021).\textsuperscript{8,15} The probabilities of recovery were calculated as the complements of the Kaplan-Meier estimates of all-cause mortality at day 28 in COV-BARRIER.\textsuperscript{8}

**Costs**

Estimates of inpatient costs were primarily sourced from an analysis of data from patients with a diagnosis of COVID-19 in the PHD, a large-scale and all-payor US hospital database of detailed information on
Table II. Treatment effectiveness inputs.

| Parameter | Parameters for Sensitivity Analysis | Source |
|-----------|--------------------------------------|---------|
|           | Value (SE) Distribution Range        |         |
| Prevalence of care postadmission, % | $\beta$ Marconi et al$^8$ |         |
| New mechanical ventilation | | |
| Placebo + SOC | 18.0 1.4 | 15.3–20.8 |
| Baricitinib + SOC | 16.4 1.3 | 13.9–19.1 |
| New noninvasive ventilation | | |
| Placebo + SOC | 13.0 1.4 | 10.4–15.9 |
| Baricitinib + SOC | 12.1 1.4 | 9.6–14.9 |
| New supplemental oxygen | | |
| Placebo + SOC | 0 0 | 0 |
| Baricitinib + SOC | 0 0 | 0 |
| Duration of care, d | Normal ACTT-2$^{15}$ data on file, Eli Lilly and Company, 2021 |
| Time to recovery | | |
| Placebo + SOC | 13.10 0.32 | 12.47–13.73 |
| Baricitinib + SOC | 12.30 0.32 | 11.67–12.93 |
| Mechanical ventilation days | | |
| Placebo + SOC | 3.46 0.46 | 2.56–4.37 |
| Baricitinib + SOC | 1.88 0.40 | 1.1–2.67 |
| Noninvasive ventilation days | | |
| Placebo + SOC | 3.44 0.26 | 2.93–3.95 |
| Baricitinib + SOC | 3.55 0.30 | 2.96–4.15 |
| Supplemental oxygen days | | |
| Placebo + SOC | 5.45 0.15 | 5.14–5.75 |
| Baricitinib + SOC | 5.67 0.23 | 5.22–6.12 |
| Probability of recovery, % | $\beta$ Marconi et al$^8$ |         |
| Noninvasive ventilation | | |
| Placebo + SOC | 69.2 4.2 | 60.1–76.6 |
| Baricitinib + SOC | 81.5 3.6 | 74.0–87.9 |
| Supplemental oxygen | | |
| Placebo + SOC | 91.1 1.6 | 87.5–93.6 |
| Baricitinib + SOC | 93.8 1.3 | 90.9–96.1 |
| Medical care w/o oxygen | | |
| Placebo + SOC | 95.8 3.0 | 87.6–98.6 |
| Baricitinib + SOC | 98.8 1.1 | 95.7–100 |

SOC = standard of care; w/o = without.
inpatient discharges (henceforth referred to as the PHD cost analysis). The data covered inpatient admissions from April 1, 2020, to September 15, 2020. The modeled population represents a mix of Medicare (52.9%), Medicaid (19.2%), and commercially insured (27.9%) patients (Table III) (data on file, Eli Lilly and Company, 2020). The data from uninsured patients were excluded from the analysis due to the unavailability of data regarding out-of-pocket costs in uninsured and self-insured patients.

From the payor perspective, direct costs included DRG payments to hospitals for the inpatient stay, costs of postacute care immediately following discharge, and lifetime all-cause health care costs among recovered patients. It was assumed that hospitals were reimbursed for the costs of care for patients with COVID-19 through DRG payments, and that drug-acquisition costs were borne by the hospital. Therefore, drug-acquisition costs were excluded from the payor perspective.

The analysis assumed that the primary determinant of the DRG used for reimbursement was the highest level of oxygen support provided during the inpatient stay. Each patient record in the PHD was assigned an MS-DRG, and the PHD cost analysis classified each patient by the highest level of oxygen support received based on the charge codes in each patient’s record (data on file, Eli Lilly and Company, 2020). These data were used to construct frequency distributions of MS-DRGs, stratified by payor type (Medicare, Medicaid, or commercial) and by highest level of inpatient care (mechanical ventilation, noninvasive ventilation, supplemental oxygen, or no oxygen). The pooled frequency distributions of Medicare, Medicaid, and commercially insured patients at each level of care were used as proxies for the MS-DRG frequency distributions of uninsured patients (see Supplemental Table S2).

Medicare payments for each MS-DRG (see Supplemental Table S3) were sourced from the Center for Medicare and Medicaid Services (CMS) public-use file of inpatient charge data by MS-DRG for fiscal year 2017. MS-DRG payments for Medicare-insured patients were increased by 20% to represent greater payments authorized by the Coronavirus Aid, Relief, and Economic Security (CARES) Act (see Supplemental Table S3). MS-DRG costs to Medicaid and commercial payors were calculated by multiplying the standard Medicare payments by reimbursement ratios sourced from the research literature (see Supplemental Table S4).

Payor costs of postacute care in the discharged submodel were specified by the duration of care and the unit-cost per day of care (Table III and see Supplemental Table S1). It was assumed that patients discharged to self-care or custodial care incurred no additional payor costs of postacute care. The duration of postacute care in each other discharge-status group was sourced from the CMS postacute care public-use file for calendar year 2017 except for short-term hospitals, which were not reported in the CMS public-use file. In the subgroup discharged to a short-term hospital, the mean inpatient hospital LOS reported in the Agency for Healthcare Research and Quality 2016 National Inpatient Sample was used as a proxy estimate for the duration of postacute care.

The unit-cost per day of home health care was derived from the CMS national, standardized 30-day period payment rate for the 2021 calendar year. Unit-costs per day of inpatient rehabilitation, skilled nursing facilities, and short-term hospitals were sourced from a longitudinal cohort study in mechanically ventilated survivors of acute respiratory distress syndrome and inflated from 2014 USD by the method described in the 2020 Institute for Clinical and Economic Review Reference Case: costs were inflated to the most recent year available (2019) using the CMS personal health care expenditure deflator, and further inflated to 2020 USD using the Bureau of Economic Analysis personal consumption expenditure price index. The unit-cost per day of long-term acute care hospitals was sourced from the March 2020 Medicare Payment Advisory Commission Report. The cost per day of hospice care was derived from CMS hospice payment rates for the 2021 fiscal year, including the service intensity add-on (0.099 h/d) for the last 7 days of life.

In the recovered submodel, payor costs consisted of all-cause health care costs of surviving patients with COVID-19. The analysis used the same age-based future health care costs reported in the Institute for Clinical and Economic Review’s CEA of remdesivir, derived from CMS National Health Expenditure Data for 2014 and inflated to 2020 USD.

For the hospital perspective, direct costs were limited to drug-acquisition costs and the medical costs of treating inpatients with COVID-19. Hospital revenues were based on DRG reimbursements received...
Table III. Cost and utility inputs.

| Parameter                                                                 | Parameters for Sensitivity Analysis | Source                                      |
|---------------------------------------------------------------------------|------------------------------------|---------------------------------------------|
|                                                                          | Value                              | Distribution                      | Range             |                                |
| Distribution of patients by payor type, %                                 |                                    | Dirichlet (N = 105,736)                | Data on file, Eli Lilly and Company, 2020 |
| Medicare                                                                  | 52.9                               | 45.6–60.2                             |                   |
| Medicaid                                                                  | 19.2                               | 16.5–21.9                             |                   |
| Private payer                                                             | 27.9                               | 17.9–37.9                             |                   |
| Uninsured                                                                 | 0                                  | 0                                       |                   |
| Hospital costs per day, mean (SE), USD                                    |                                    | Normal                                 | Data on file, Eli Lilly and Company, 2020 |
| Mechanical ventilation                                                    | 3660 (78.64)                       | 3506–3814                             |                   |
| Noninvasive ventilation                                                   | 2450 (124.99)                      | 2205–2695                             |                   |
| Supplemental oxygen                                                       | 1828 (19.05)                       | 1791–1865                             |                   |
| Medical care w/o oxygen                                                   | 1818 (13.40)                       | 1792–1844                             |                   |
| Payor costs per patient, by highest level of inpatient care, USD* USD     |                                    |                                        |                   |
| Inpatient hospitalization costs                                           |                                    |                                        |                   |
| Mechanical ventilation                                                    | 48,884                             |                                        |                   |
| Noninvasive ventilation                                                   | 17,468                             |                                        |                   |
| Supplemental oxygen                                                       | 17,241                             |                                        |                   |
| Medical care w/o oxygen                                                   | 16,946                             |                                        |                   |
| Post-discharge COVID-19 costs, USD                                        |                                    |                                        |                   |
| Mechanical ventilation                                                    | 8716                               |                                        |                   |
| Noninvasive ventilation                                                   | 3527                               |                                        |                   |
| Supplemental oxygen                                                       | 2388                               |                                        |                   |
| Medical care w/o oxygen                                                   | 2165                               |                                        |                   |
| Per-annum all-cause medical costs post recovery among patients without serious comorbidities, USD | Normal | Whittington⁹ | |
| Age 19–44 y                                                               | 5741 (150)                         | 4593–6889                             |                   |
| Age 45–64 y                                                               | 12,073 (200)                       | 9658–14,488                           |                   |
| Age 65–84 y                                                               | 20,071 (250)                       | 16,057–24,085                         |                   |
| Age 85+ y                                                                 | 38,900 (300)                       | 31,120–46,680                         |                   |
| Indirect costs                                                            |                                    |                                        |                   |
| Percent of patients employed, %                                           | 32.4 (5)                           | 25.9–38.9                             |                   |

(continued on next page)
from payors. The cost of acquiring remdesivir 100 mg was sourced from publicly disclosed pricing for governmental payors (390 USD) and nongovernmental payors (520 USD), and was prorated by the percentage of patients (18.9%) receiving concurrent remdesivir as SOC in the COV-BARRIER trial. The cost per baricitinib 2-mg tablet (75.50 USD) was calculated by prorating the wholesale acquisition cost of a 30-day supply. Unit-costs per day of treatment at each level of oxygen support (Table III) were sourced from the PHD cost analysis (data on file, Eli Lilly and Company, 2020), and reimbursement payments were based on the same inputs and methods used to calculate DRG payments in the payor perspective.

Indirect costs were included only in the payor perspective and did not factor into the CEA in the hospital perspective. Indirect costs were estimated by multiplying the percentage of patients employed in Table III. (continued)

| Parameter | Parameters for Sensitivity Analysis | Source |
|-----------|-------------------------------------|--------|
| Cost per workday missed, USD | 218.63 (25) | US Bureau of Labor Statistics, Garfield et al, Whittington, Campbell et al, Sullivan and Ghushchyan, Campbell et al, Smith and Roberts, Barbut et al, Sackett and Torrance |
| Age-based utilities among patients without severe comorbidities | | |
| Age 18–29 y | 0.922 (0.0019) | 0.918–0.926 |
| Age 30–39 y | 0.901 (0.0021) | 0.897–0.905 |
| Age 40–49 y | 0.871 (0.0024) | 0.866–0.876 |
| Age 50–59 y | 0.842 (0.0028) | 0.836–0.847 |
| Age 60–69 y | 0.823 (0.0034) | 0.816–0.830 |
| Age 70–79 y | 0.790 (0.0036) | 0.783–0.797 |
| Age 80+ y | 0.736 (0.0062) | 0.724–0.748 |
| Disutilities of hospitalization for COVID-19 | Normal | Campbell et al, Sullivan and Ghushchyan, Smith and Roberts, Barbut et al, Sackett and Torrance |
| COVID-19 symptoms | −0.190 (0.022) | −0.233 to −0.147 |
| Mechanical ventilation | −0.600 (0.045) | −0.688 to −0.512 |
| Noninvasive ventilation | −0.500 (0.045) | −0.588 to −0.412 |
| Supplemental oxygen | −0.400 (0.045) | −0.488 to −0.312 |
| Medical care w/o oxygen | −0.300 (0.045) | −0.388 to −0.212 |

USD = US dollars; w/o = without.

* Payor costs per patient by highest level of inpatient care were calculated in the model based on the inputs shown in Supplemental Tables S4 and S5; parameters for the sensitivity analyses associated with those parameters are also shown in Supplemental Tables S4 and S5.

† See the online version at doi:10.1016/j.clinthera.2021.09.016.
full-time (32.4%) by the hospital LOS and cost per workday (218.63 USD) (Table III). The percentage of patients with full-time employment was calculated by weighting the percentages of employed patients in each subgroup of payor type by the distribution of payors estimated from the PHD cost analysis (Table I) (data on file, Eli Lilly and Company, 2020). The percentage of Medicare-insured patients with full-time employment was assumed to be equal to the percentage of the population aged ≥65 years with full-time employment (11.6%). The percentage of Medicaid-insured patients with full-time employment (48.0%) was sourced from a report by the Kaiser Family Foundation. The percentage of commercially insured patients with full-time employment was assumed to be the percentage of the US population aged 20 to 64 years with full-time employment (61%). The cost per workday missed was based on employer costs of employee compensation from the Bureau of Labor Statistics (38.26 USD) and the assumption of 40 hours per week for full-time employment.

**Health Utilities**

Health utilities (Table III) were modeled by extending the approach used in the Institute for Clinical and Economic Review’s evaluation of remdesivir. Age-adjusted health utilities for the US general population were used to represent overall quality of life absent the effects of COVID-19. These utilities were adjusted to account for the greater prevalence of comorbidities in the modeled population (Table I).

In the inpatient submodel, the disutility associated with influenza in prior economic modeling was used as a proxy estimate of the disutility associated with COVID-19 symptoms, and disutilities associated with hospitalization and ventilation were derived from a quality-of-life study from France in patients hospitalized for the treatment of *Clostridium difficile* infection. The Institute for Clinical and Economic Review model did not contain a corresponding health state for supplemental oxygen, and so the disutility of this state in the CEM was interpolated as the midpoint between non-invasive ventilation and medical care without oxygen (Table III).

In the discharged submodel, reduced quality of life among patients requiring postacute care was simulated by relative utility multipliers sourced from the literature (see Supplemental Table S1). Relative utilities associated with inpatient rehabilitation and skilled nursing facility care were estimated by replicating the approaches used in a published CEM of severe chronic obstructive pulmonary disease. The relative utility of inpatient rehabilitation was derived from a quality-of-life study in patients with myocardial infarction who underwent 8-week inpatient rehabilitation, while the relative utility associated with a skilled nursing facility was derived from a CEA of osteoporosis. A derived estimate of the relative utility of hospice care was calculated as the quotient of the utility of hospice divided by the utility of progression-free survival in a published CEA of ovarian cancer. In the absence of available evidence, the relative utility of home health care was assumed to be identical to the relative utility of inpatient rehabilitation, and the relative utilities of a short-term hospital and a long-term acute care hospital were assumed to be the same as the relative utility of a skilled nursing facility.

In the recovered submodel, the health utilities of patients recovered from COVID-19 were assumed to be the same as the age-adjusted health utilities of the general US population, adjusted to account for the greater prevalence of comorbidities among hospitalized patients with COVID-19 (see the earlier discussion of comorbidities in the population subsection).

**Other Inputs**

Treatment dosing and administration inputs assumed that remdesivir was administered by infusion as a single loading dose of 200 mg on day 1, followed by daily doses of 100 mg during hospitalization for up to 10 days, and that baricitinib was administered orally as a daily dose of 4 mg during hospitalization for up to 14 days. Age- and sex-adjusted all-cause mortality rates were sourced from the Social Security Administration Period Life Table of 2017. The discounted rates for costs and QALY were set to 3% per annum.

**Model Base-Case, Scenarios, and Sensitivity Analyses**

For the base case, we evaluated the cost-effectiveness of baricitinib + SOC versus placebo + SOC in hospitalized patients with COVID-19 using efficacy data from the COV-BARRIER trial, from a health payor perspective over a lifetime horizon, which accounted for long-
term direct medical costs. In a secondary "mortality-only" analysis, we examined the cost-effectiveness of baricitinib + SOC versus placebo + SOC, assuming that the statistically significant reduction in mortality demonstrated in COV-BARRIER was the only benefit with baricitinib treatment. We tested the impact of parameter uncertainty on the results of the primary analysis through deterministic sensitivity analysis and PSA. We also examined the cost-effectiveness of baricitinib + SOC from the hospital perspective.

RESULTS

Payor Perspective

Base-Case and Scenario Results

With baricitinib + SOC versus placebo + SOC, the incremental total cost was 17,276 USD, total QALY gained was 0.6703, and total LY gained was 0.837 (Table IV). The primary components of the incremental results were the greater lifetime all-cause medical costs (17,673 USD) and lifetime QALYs (0.6669) accrued by patients who survived and recovered from COVID-19 (see Supplemental Table S5). In the base-case analysis, the incremental cost-effectiveness ratios (ICERs) of adjunctive treatment with baricitinib were 25,774 USD/QALY gained and 20,638 USD/LY gained—only slightly greater than the base case (Table IV).

Deterministic (One-Way) Sensitivity Analysis

The 10 most sensitive inputs identified through one-way sensitivity analysis in the base-case analysis from the payor perspective are shown in Figure 2. The base-case results were most sensitive to uncertainty regarding the lifetime all-cause health care costs among recovered patients, followed by progression to mechanical ventilation during the inpatient stay. The ICER was between 20,000 and 32,000 USD for all variables explored in the one-way sensitivity analysis, which fell well within the threshold of 50,000 USD/QALY gained recommended by the Institute for Clinical and Economic Review.

Probabilistic Sensitivity Analysis

A PSA of the base-case analysis was implemented in Excel software (Microsoft, Redmond, Washington) with 5000 replications (Figure 3). Compared with SOC alone, adjunctive treatment with baricitinib was associated with a cost increase of 17,373 USD (95% CI, –3300 to 38,306) and a clinical effect increase of 0.674 QALYs (95% CI, –0.096 to 1.441). The cost-effectiveness acceptability curve indicated that adjunctive treatment with baricitinib was cost-effective at a willingness-to-pay threshold

Table IV. Cost-effectiveness results for baricitinib + SOC versus placebo + SOC, from the payor’s perspective.

| Scenario and arm                  | Total Costs, USD | Total QALYs Gained | Total LYs Gained | Cost per QALY Gained, USD | Cost per LY Gained, USD |
|----------------------------------|------------------|--------------------|-----------------|---------------------------|-------------------------|
| **Base case**                    |                  |                    |                 |                           |                         |
| Placebo + SOC                    | 329,268          | 11.3879            | 14.300          |                           |                         |
| Baricitinib + SOC                | 346,544          | 12.0582            | 15.137          |                           |                         |
| Incremental, baricitinib vs placebo | 17,276          | 0.6703             | 0.837           | 25,774                    | 20,638                  |
| **Mortality only**               |                  |                    |                 |                           |                         |
| Placebo + SOC                    | 329,268          | 11.3879            | 14.300          |                           |                         |
| Baricitinib + SOC                | 347,170          | 12.0544            | 15.136          |                           |                         |
| Incremental, baricitinib vs placebo | 17,902          | 0.6664             | 0.835           | 26,862                    | 21,433                  |

LY = life-years; QALY = quality-adjusted life-years; SOC = standard of care; USD = US dollars.
Figure 2. Deterministic sensitivity analysis tornado diagram with 10 most sensitive inputs for base case (payer perspective) with an incremental cost-effectiveness ratio (ICER) = $25,774 US dollars.

Figure 3. Probabilistic sensitivity analysis cost-effectiveness plane for baricitinib + standard of care (SOC) vs placebo + SOC, with 5000 replications for the base case from private payor perspective. Costs versus quality-adjusted life-years (QALYs), with a 50,000 US dollars willingness-to-pay (WTP) threshold for comparison.
of 50,000 USD/QALY gained in 96.5% of the PSA replications.

**Hospital Perspective**

We also ran secondary analyses from a hospital perspective. In the base-case hospital perspective analysis, treatment with baricitinib + SOC was both more effective and less costly than treatment with placebo + SOC. Adding baricitinib to SOC reduced total hospital expenditures by 2436 USD and reduced total reimbursement payments by 503 USD, resulting in a 1932 USD reduction in net costs. It also resulted in a net gain of 0.0023 QALYs, reduced the use of mechanical ventilation by 1.6%, and increased survival by 5.1% (see Supplemental Table S6). In the mortality-only scenario analysis, the addition of baricitinib to SOC increased hospital expenditures by 1978 USD and increased survival by 5.1%, resulting in an incremental cost of 38,964 USD per death avoided (see Supplemental Table S6).

**Net Impact on Clinical Outcomes**

Net impacts on clinical outcomes are presented in the Appendix. Compared with placebo + SOC, treatment with baricitinib + SOC reduced the use of mechanical ventilation by 16 patients per 1000 treated and reduced the use of noninvasive ventilation by 7 patients per 1000 treated. Similarly, treatment with baricitinib + SOC reduced the total hospital LOS by 800 days per 1000 patients treated, with the decrease mainly driven by a decrease of 1580 days of mechanical ventilation per 1000 patients treated.

**DISCUSSION**

We conducted an economic evaluation on the use of baricitinib + SOC versus placebo + SOC among hospitalized patients with COVID-19 in a US setting, based on the outcomes from the Phase III COV-BARRIER trial. A de novo CEM was developed by extending the methods used in the Institute for Clinical and Economic Review’s evaluation of remdesivir to support a hospital perspective and to account for discharge status, postacute care, and the greater prevalence of comorbidities among hospitalized patients with COVID-19.

In the base-case analysis from the payor perspective, with baricitinib + SOC, the incremental cost per QALY gained was 25,774 USD, and the cost per LY gained was 20,638 USD. In the mortality-only scenario analysis, which limited the treatment benefit of baricitinib to the statistically significant reduction in mortality demonstrated in COV-BARRIER, the ICERs were 26,862 USD/QALY gained and 21,433 USD/LY gained—only slightly greater than the base case. The principal drivers of the incremental results with baricitinib were the greater lifetime all-cause medical costs and greater lifetime QALYs accrued by recovered patients due to the greater survival rate. The robustness of the results in the mortality-only scenario analysis, deterministic sensitivity analysis, and the PSA provides further evidence that baricitinib + SOC is cost-effective versus SOC alone at the conservative willingness-to-pay threshold of 50,000 USD/QALY gained recommended by the Institute for Clinical and Economic Review, even when lifetime all-cause medical costs were factored into the analysis.

The base-case analysis from the hospital perspective indicated that adjunctive treatment with baricitinib reduces total hospital expenditures, primarily by reducing the number of patients who require mechanical ventilation. Given that patients requiring mechanical ventilation were reimbursed via more expensive DRGs, reimbursement payments were also reduced. However, the reduction in hospital expenditures was greater than the reduction in reimbursement payments, producing an overall savings in net costs (expenses minus reimbursement). With baricitinib + SOC, QALYs were also greater; therefore, baricitinib + SOC was a dominant strategy (lesser costs and greater effectiveness) compared with SOC alone. In the mortality-only scenario analysis from the hospital perspective, with adjunctive treatment with baricitinib, the incremental cost was 38,964 USD per death avoided.

The COVID-19 pandemic continues, and new variant strains are emerging, despite the increasing percentage of vaccinated population. Thus, decision makers will continue to rely on CEAs to assess the relative value of emerging treatments. Evidence on the CEA of COVID-19 treatments in the United States is limited. Remdesivir, the first treatment approved by the US Food and Drug Administration for use in patients with COVID-19, was evaluated by the Institute for Clinical and Economic Review using a CEM, without consideration of discharge status or postacute care outcomes of patients, nor was the hospital perspective evaluated. While the Institute...
for Clinical and Economic Review’s model simulated a lifetime horizon using mortality and cost and QALY estimations from the general population, the poorer health of hospitalized patients with COVID-19 due to more comorbidities vis-à-vis the general population was not addressed.

Our model overcame those key limitations by considering total hospital expenditures, reimbursement payments, and net costs per QALY gained. Our model explicitly considered the health outcomes and costs by discharge status (self-care or custodial care, home health care, inpatient rehabilitation, skilled nursing facility care, short-term hospitalization, long-term acute care hospitalization, and hospice status) to provide an overall picture of postacute hospital consequences. Also, the mortality-related calculations in our model accommodated a wide range of age groups, and the long-term all-cause health care costs reflected the impact of comorbidities in this population. Another major strength of our model was the use of detailed data on inpatient and discharge status from patients with COVID-19 in clinical practice in the United States from the PHD. The flexible and realistic features of the model allowed for adaptations for use outside the United States.

Data on the possible long-term burden of COVID-19 have only recently emerged.\(^{58,59}\) Thus, our model, as well as other existing CEMs, did not consider the long-term consequences of COVID-19 due to a lack of data.\(^{60}\) Although our model estimated the potential impact of efficacious therapies that can reduce progression to greater levels oxygen care, and therefore reductions in hospital and intensive care unit LOSs, these potential benefits to hospitals in terms of alternative, non COVID-19–related care were not directly quantified. Another limitation specific to our hospital data inputs was the potential lack of generalizability of these national estimates to individual hospitals. Also, our hospital costs did not include COVID-19–related hospital readmissions. Finally, the model assumed that recovered patients incurred all-cause health care costs, health utilities, and all-cause mortality based on the general non–COVID-19 infected population, adjusted to reflect greater rates of comorbidities in the modeled COVID-19 population, but not reflective of currently indeterminant long-term COVID-19 sequelae.

CONCLUSIONS
In the present analysis, baricitinib in combination with SOC in patients hospitalized due to COVID-19 infection in the United States was cost-effective. These results were robust across multiple sensitivity analyses and scenarios in the model and were driven by the reduced risk for mortality with baricitinib treatment.

AUTHOR CONTRIBUTIONS
R.O.: design of the work and interpretation of the data; T.S. and M.B.: concept and design of the work, interpretation of data; P.M.: concept and design of the work, acquisition and interpretation of data; K.K. and T.K.: concept and design of the work, acquisition, analysis, and interpretation of data; R.B.: concept of the work, acquisition and interpretation of the data; N.A.: interpretation of the data.

FUNDING
This study was funded by Eli Lilly and Company (K.K. and T.K.).

DISCLOSURE
K.K. and T.K. are employees of Medical Decision Modeling Inc and received funding from Eli Lilly and Company to conduct the study. P.L.M., T.S., R.B., and M.B. are employees of Eli Lilly and Company. The authors have indicated that they have no other conflicts of interest with regard to the content of this article.

ACKNOWLEDGMENTS
Pamela Martin, Medical Decision Modeling Inc, provided writing support.

REFERENCES
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
2. World Health Organization. Timeline: WHO’s COVID-19 Response 2020 [WHO website]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline. Accessed June 23, 2021.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. [WHO website]. Available from: https://covid19.who.int. Accessed June 23, 2021.
4. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24:308–317.
5. Centers for Disease Control and Prevention. COVID Data Tracker. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed June 23, 2021.

6. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39:1157–1164.

7. US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 [FDA website]. 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19. Accessed March 23, 2021.

8. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib in patients with COVID-19 infection: results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial. Lancet Respir Med. 2021. Epub ahead of print. In press https://www.thelancet.com/journals/lancres/article/PIIS2213-2600(21)00331-3/fulltext. doi:10.1016/S2213-2600(21)00331-3.

9. Whittington CJ. Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19 [Institute for Clinical and Economic Review website]. June 24 2020; Available from: https://icer.org/news-insights/press-releases/updated_icer-covid_models_june_24. Accessed April 23, 2021.

10. Campbell JD WM, Rind DM, Pearson SD. Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19; Updated Report. [Institute for Clinical and Economic Review website]. November 10, 2020. Available from: http://icer.org/wp-content/uploads/2020/11/ICER-COVID_Updated_Report_11102020.pdf. Accessed April 23, 2020.

11. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826.

12. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–1057.

13. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2020;384:693–704.

14. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. medRxiv. [Preprint].

15. A Multicenter, Adaptive, Randomized Blinded Controlled Study of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults. ACTT-2: Baricitinib/Remdesivir vs Remdesivir. Final Integrated Clinical/Statistical Report [Adis Insight database]. 2020. Available from: https://journals.adis.com/journals/lancet/article/PiIs2213-2600(21)00331-3/fulltext. doi:10.1016/S2213-2600(21)00331-3.

16. Premier Healthcare Database White Paper: Data that Informs and Performs [Premier Applied Sciences website]. 2020. Available from: https://learn.premierinc.com/white-papers/premierhealthcaredatabase. Accessed March 2, 2020.

17. Labor Force Statistics from the Current Population Survey [US Bureau of Labor Statistics website]. 2021. Available from: https://data.bls.gov/PDQWeb/in. Accessed February 26, 2021.

18. Boudreau DM, Malone DC, Raebel MA, et al. Healthcare utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009;7:305–314.

19. Vetter ML, Wadden TA, Lavenberg J, et al. Erratum: relation of health-related quality of life to metabolic syndrome, obesity, depression, and comorbid illness. Int J Obes. 2012;36:325–326.

20. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–1778.

21. Garfield R RR, Guth M, Ortega K, Hinton E, Neuman T. Work Among Medicaid Adults: Implications of Economic Downturn and Work Requirements [Kaiser Family Foundation website]. 2021. https://www.kff.org/report-section/work-among-medicaid-adults-implications-of-economic-downturn-and-work-requirements-issue-brief/. Accessed March 1, 2021.

22. Employer Costs for Employee Compensation. Series ID: CMU10100000000000D (C). All Civilian Total Compensation for All Occupations: Cost per Hour Worked, 2010 to 2020 [US Bureau of Labor Statistics website]. 2021. Available from: https://www.bls.gov/data/. Accessed February 26, 2021.

23. Sullivan PW, Ghushchyan V. Preference-based EQ-SD index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410–420.

24. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113:300–307.

25. Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility...
decrement associated with Clostridium difficile infection in a French hospital setting. *Health Qual Life Outcomes*. 2019;17:6.

26. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. *J Chronic Dis.* 1978;31:697–704.

27. Centers for Medicare and Medicaid Services. National Summary of Inpatient Charge Data by Medicare Severity Diagnosis Related Group (MS-DRG), FY 2017, Interactive Dataset. 2019. Accessed October 9, 2020.

28. New Waivers for Inpatient Prospective Payment System (IPPS) Hospitals, Long-Term Care Hospitals (LTCHs), and Inpatient Rehabilitation Facilities (IRFs) due to Provisions of the CARES Act [MLN Matters online]. 2020. Available from: https://www.cms.gov/regulations-and-guidanceregulationsandtransmittals2020/transmittals/se20015. Accessed March 1, 2021.

29. Medicaid and CHIP Payment Access Commission (MACPAC). Medicaid Hospital Payment: A Comparison Across States and to Medicare [MACPAC website]. 2017. Available from: https://www.macpac.gov/publication/medicaid-hospital-payment-a-comparison-across-states-and-to-medicare. Accessed August 21, 2020.

30. Lopez E, Claxton G, Schwartz K, Rae M, Ochieng N, Neuman T. Comparing Private Payer and Medicare Payment Rates for Select Inpatient Hospital Services [Kaiser Family Foundation website]. 2020. Available from: https://www.kff.org/medi cere/issue-brief/comparing-private-payer-and-medicare-payment-rates-for-select-inpatient-hospital-services. Accessed August 21, 2020.

31. Centers for Medicare and Medicaid Services. Medicare Fee-For-Service Post-Acute Care Provider Public Use Files, Calendar Year 2017 Provider Table [CMS website]. 2020. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/PAC2017. Accessed November 13, 2020.

32. Freeman WJ, Weiss AJ, Heslin KC. Overview of U.S. Hospital Stays in 2016: Variation by Geographic Region. 2018 [Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project website]. 2020. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb246-Geographic-Variation-Hospital-Stays.jsp. Accessed November 13, 2020.

33. Centers for Medicare and Medicaid ServicesMedicare and Medicaid programs; CY 2021 home health prospective payment system rate update, home health quality reporting program requirements, and home infusion therapy services and supplier enrollment requirements; and home health value-based purchasing model. *Fed Reg.* 2020;85(214):70298–70356. https://www.govinfo.gov/content/pkg/FR-2020-11-04/pdf/2020-24146.pdf. Accessed March 1, 2020.

34. Ruhl AP, Huang M, Colantuoni E, et al. Healthcare utilization and costs in ARDS survivors: a 1-year longitudinal national US multicenter study. *Intensive Care Med.* 2017;43:980–991.

35. Institute for Clinical and Economic Review. ICER’s Reference Case for Economic Evaluations: Principles and Rationale [ICER website]. 2020. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Reference_Case_013120.pdf. Accessed June 14, 2021.

36. Centers for Medicare and Medicaid Services. Table 23. National Health Expenditures; Nominal Dollars, Real Dollars, Price Indexes, and Annual Percent Change: Selected Calendar Years 1980-2019 [CMS website]. 2020. Available from: https://www.cms.gov/files/zp/nhe-tables.zip. Accessed June 14, 2021.

37. Bureau of Economic Analysis. Table 2.3.4. Price Indexes for Personal Consumption Expenditures by Major Type of Product [BEA website]. 2021. Available from: https://apps.bea.gov/iTable/iTable.cfm?reqid=19&step=3&isuri=1&1921survey1903=84. Accessed March 3, 2021.

38. MPAC. Chapter 11: Long-term care hospital services. In: Report to the Congress: Medicare Payment Policy [MedPAC website]. March 2020. Available from: http://www.medpac.gov/docs/default-source/reports/mar20_entirereport_rev_sec.pdf?sfvrsn=0. Accessed August 21, 2020.

39. Centers for Medicare and Medicaid Services. Update to Hospice Payment Rates, Hospice Cap, Hospice Wage Index and Hospice Price for FY 2021. Medical Learning Network 2020; MM111876 [CMS website]. September 24, 2020. https://www.cms.gov/files/document/mm111876.pdf. Accessed March 3, 2021.

40. Martin K, Diessen J. Preliminary evidence of the impact of hospice payment reform on social service visits in the last week of life. *J Palliat Med.* 2020;23:1377–1379.

41. Duncan I AT, Dove H, Maxwell T. Medicare cost at end of life. *Am J Hospice Pall Med.* 2019;36:705–710.

42. Institute for Clinical and Economic Review. Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19 [ICER website]; 2020 June 14. Available from: https://icer.org/wp-content/uploads/2020/10/ICER-COVID_Revised_Report_20200624.pdf. Accessed June 24, 2020.

43. Centers for Medicare and Medicaid Services. National Health Expenditure Data, Age and Gender, Health Expenditures by Age and Gender[ CMS website]; 2020 Available from:
https://www.cms.gov/
Research-Statistics-Data-and-Systems/
Statistics-Trends-and-Reports/
NationalHealthExpendData/
Age-and-Gender Accessed November 13, 2020.

44. O’Day D. An Open Letter From Daniel O’Day, Chairman & CEO, Gilead Sciences [Gilead website]. 2020. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday- (?PMU?)chairman-ceo-gilead-sciences. Accessed October 29, 2020.

45. Olumiant (baricitinib) [price information]. 2020. Available from: www.lillypricinginfo.com/olumiant. Accessed October 29, 2020.

46. Hajizadeh N CK, Braithwaite RS. Informing shared decisions about advance directives for patients with severe chronic obstructive pulmonary disease: a modeling approach. Value Health. 2012;15:357–366.

47. Oldridge N, Furlong W, Feeny D, et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol. 1993;72:154-161.

48. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583–637.

49. Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med. 1986;80:1115–1127.

50. Wysham WZ, Schaffer EM, Coles T, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecol Oncol. 2017;145:340–345.

51. Veklury (remdesivir) [prescribing information]. 2020. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf. Accessed November 2, 2020.

52. US Social Security Administration. Actuarial Life Table. Period Life Table, 2017 [SSA website]. Available from: https://www.ssa.gov/oact/HistEst/PerLifeTables/2017/PerLifeTables2017.html. Accessed July 30, 2020.

53. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health. 1998;1:131–147.

54. Institute for Clinical and Economic Review. ICER 2020-2023 Value Assessment Framework [ICER website]. 2020. https://icer.org/wp-content/uploads/2021/03/ICER_2020_2023_VAF_013120-4.2.pdf. Accessed March 3, 2021.

55. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093–1103.

56. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38:1811–1831.

57. Institute for Clinical and Economic Review. ICER update to pricing models of remdesivir for COVID-19. Pharmacoecon Outcomes News. 2020;857:2-2.

58. del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324:1723–1724.

59. Miller IF, Becker AD, Grenfell BT, Metcalf CJ. Disease and healthcare burden of COVID-19 in the United States. Nature Med. 2020;26:1212–1217.

60. Taribagil P, Creer D, Tahir H. Long COVID’ syndrome. BMJ Case Rep. 2021;14.

61. Kalil AC, Patterson TF, Mehta AK, Tomaszek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchoña H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Ruphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807. doi:10.1056/NEJMoa2031994. Epub 2020 Dec 11. PMID: 33306283; PMCID: PMC7745180.

Address correspondence to: Russel Burge, PhD, Eli Lilly and Company, 893 South Delaware Street, Indianapolis, IN 46225. E-mail: rburge@lilly.com.
SUPPLEMENTARY MATERIALS
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.clinthera.2021.09.016.

SUPPLEMENTARY APPENDIX 1. DETAILS OF THE MODEL STRUCTURE
The model is structured as three submodels (Figure A1):

1. Inpatient: Algebraic model of the inpatient stay from admission to discharge. This phase accounts for the effects of treatment on health outcomes, which in turn determine the costs expended by the hospital, reimbursement payments received from insurers, and patient quality of life while hospitalized.

2. Discharge: Algebraic model of the potential for follow-up care, such as discharge to a rehabilitation facility, skilled nursing facility, long-term acute care hospital, hospice, or self-care. This phase accounts for the impact of prolonged care on costs and the patient’s quality of life immediately following discharge.

3. Recovered: Markov model of the remaining life years after the patient recovers from COVID-19.

This phase accounts for the costs and benefits of reducing mortality associated with COVID-19.

1.1 Inpatient Submodel
The inpatient submodel is an algebraic model that calculates the costs and QALYs accrued during the inpatient stay through a sequence of matrix operations (Figure A2). The key drivers of cost effectiveness during the inpatient stay are the total patient-days at each level of care (expenses and QALYs) and the distribution of patients by highest level of care (DRGs and reimbursements). Treatment effects on mortality do not directly affect inpatient costs and QALYs but have downstream effects in the discharge and recovered submodels.

1.2 Discharge Submodel
The discharge submodel is an algebraic model that calculates the costs and QALYs accrued during the post-discharge follow-up period through a sequence of matrix operations (Figure A3). The submodel assumes that patients discharged to hospice die at the end of their hospice stay, and patients discharged to any other status enter the recovered submodel at the end of the follow-up period.

1.3 Recovered Submodel
The recovered submodel is a Markov model that simulates patients after they have recovered and completed any required post-discharge follow-up care (Figure A4). The purpose of this submodel is to account for the costs and QALY benefits of treatment effects on COVID-related mortality. It is a simple Markov model with two states, alive or dead, that simulates all-cause mortality over a lifetime horizon. Costs incurred during this phase may be excluded from the analysis by the user if they are considered beyond the scope of the payer (hospital, Medicare, Medicaid, private insurer, or the patient). The assumption is that recovered COVID-19 patients incur all-cause healthcare costs, health utilities, and all-cause mortality based on the general non-COVID-19 infected population, adjusted to reflect higher rates of comorbidities in the modeled COVID population.
Figure A2. Flow of calculations in the inpatient submodel.

Note: The color coding is as follows: dark blue, treatment-specific user inputs; no fill, non-treatment-specific user inputs; grey, interim calculations in the inpatient submodel; red, top-line results; green, interim results passed to the discharge submodel.

Abbreviations: COVID, coronavirus disease; DRG, diagnosis-related group; QALY, quality-adjusted life year.
Figure A3. Flow of calculations in the discharge submodel.

Note: The color coding is as follows: no fill, non-treatment-specific user inputs; grey, interim calculations in the discharge submodel; red, top-line results; green, interim results passed to and from other submodels.

Abbreviations: QALY, quality-adjusted life year.
Note: The color coding is as follows: no fill, non-treatment-specific user inputs; grey, health states in the Markov submodel; red, top-line results; green, interim results passed to and from other submodels.
Abbreviations: QALY, quality-adjusted life year.

Figure A4. Flow of calculations in the recovered submodel